Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Evolus, Inc.

EOLSNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.34
$-0.08(-1.80%)
U.S. Market is Open • 14:23

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap283.3M
P/E Ratio-4.82
EPS (TTM)$-0.90
ROE4.83%
Fundamental Analysis

AI Price Forecasts

1 Month$1.73
3 Months$2.22
1 Year Target$0.00

EOLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Evolus, Inc. (EOLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 36.16, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.82 and a market capitalization of 283.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.13%
5-Day Change
1.86%
1-Month Change
-13.64%
3-Month Change
-33.99%
6-Month Change
-39.56%
Year-to-Date (YTD) Change
-34.97%
1-Year Change
-70.11%
3-Year Change
-50.23%
5-Year Change
-60.24%
All-Time (Max) Change
-62.00%

Contact Information

949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

3,720 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions